Dianthus Therapeutics Inc. (NASDAQ: DNTH) announced it reached an early GO decision for its Phase 3 CAPTIVATE trial of claseprubart ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE